Delivery Order SPE2DB20D7059-SPE2DB25FQLJ7
- Not listed
- The Defense Logistics Agency awarded a $2,348.61 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors on September 4, 2025, with a completion date of September 5, 2025. This competitively awarded, firm fixed-price contract has no set-aside designation and is performed at the contractor's facility in Conshohocken, Pennsylvania. Emgality is a calcitonin gene-related peptide monoclonal antibody used in migraine prevention, reflecting the Defense Logistics Agency's...
- The Defense Logistics Agency awarded a $5,864.45 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on September 4, 2025, with completion targeted for September 5, 2025. This non-competitive delivery order represents a firm fixed price transaction under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody...
- The Defense Logistics Agency awarded a $1,729.00 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract executed on August 8, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Emgality is a calcitonin gene-related peptide (CGRP) antagonist used for migraine prevention, representing the type of specialty...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors. This non-set-aside, competitively awarded contract was issued on September 16, 2025, with an ultimate completion date of September 17, 2025, and reflects a firm fixed-price delivery order structure. The product will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Emgality 120 mg/ml pen injectors, with a ceiling value of $1,554.86. This firm fixed-price delivery order is scheduled for completion by July 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made without a set-aside designation, indicating open competition. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,530.62 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of September 17, 2025. This competitive award uses firm fixed pricing with no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,729.00 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. This competitively awarded, firm fixed-price delivery order was issued on June 2, 2025, with an ultimate completion date of June 3, 2025. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and...
- The Defense Logistics Agency (DLA) awarded a $1,355.21 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injections on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The prime contractor, headquartered in Conshohocken, Pennsylvania, is a major...
- The Defense Logistics Agency awarded a $1,729.00 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors under a firm fixed price contract. This non-competitive, non-set-aside delivery order was executed on August 14, 2025, with an ultimate completion date of August 15, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Emgality is a migraine prevention medication, reflecting the government's ongoing need for...
- The Defense Logistics Agency awarded a delivery order valued at $1,213.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, with an ultimate completion date of July 29, 2025. The contract, issued on July 28, 2025, employs firm fixed-price pricing and was awarded through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a...
- SPE2DB20D7059Indefinite Delivery Contract
- SPE2DB20D7059-SPE2DB25FQLJ7Delivery Order
The Defense Logistics Agency awarded a $1,037.40 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors under a firm fixed price contract with an ultimate completion date of July 15, 2025. The award, issued on July 14, 2025, represents a non-set-aside competitive procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Emgality is a calcitonin gene-related peptide (CGRP) antagonist used for migraine prevention and treatment, reflecting DLA's ongoing procurement of specialized pharmaceutical products to support military and federal healthcare systems. This delivery order derives from AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical prime vendor for federal medical procurement, supplying a comprehensive range of brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 7/14/25 |